This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00826/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00826/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/mixture/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00826/identifier/kegg-compound/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00826/identifier/pubchem-compound/
n9http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00826/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00826/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00826/identifier/drugbank/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00826/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://www.drugs.com/cdi/
n24http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00826
rdf:type
n3:Drug
n3:description
Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
n3:dosage
n20:271B4702-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including <i>Fusarium solani</i> keratitis.
n3:manufacturer
n11:271B4700-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00826 n10:DB00826
dcterms:title
Natamycin
adms:identifier
n13:PA164744325 n14:Natamycin n15:46509171 n16:5281099 n17:D00884 n18:0065-0645-15 n19:DB00826 n21:C08073
n3:mechanismOfAction
LIke other polyene antibiotics, Natamycin inhibits fungal growth by binding to sterols. Specifically, Natamycin binds to ergosterol in the plasma membrane, preventing ergosterol-dependent fusion of vacuoles, as well as membrane fusion and fission. This differs from the mechanism of most other polyene antibiotics, which tend to work by altering fungal membrane permeability instead.
n3:packager
n11:271B46FF-363D-11E5-9242-09173F13E4C5
n3:synonym
Natamycin Pimaricin Natamicina PMR Natacyn Natamycine Natamycinum
n3:mixture
n26:271B46FE-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Michael A. Eisenschink, Phillip T. Olson, "Fermentation process for producing natamycin." U.S. Patent US5231014, issued July, 1982.
foaf:page
n23:natamycin.html n24:natamycin.htm
n3:IUPAC-Name
n4:271B4707-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B470D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B470C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4709-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B470A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B470B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4705-363D-11E5-9242-09173F13E4C5 n4:271B471D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4703-363D-11E5-9242-09173F13E4C5 n4:271B4706-363D-11E5-9242-09173F13E4C5 n4:271B471F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4704-363D-11E5-9242-09173F13E4C5 n4:271B4720-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:A07AA03 n6:D01AA02 n6:S01AA10 n6:G01AA02 n6:A01AB10
n3:H-Bond-Acceptor-Count
n4:271B4713-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4714-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B470E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B470F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4711-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4710-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4712-363D-11E5-9242-09173F13E4C5
n3:absorption
Systemic absorption should not be expected following topical administration, and as with other polyene antibiotics, absorption from the gastrointestinal tract is very poor.
n3:affectedOrganism
Various Fungus Species
n3:casRegistryNumber
7681-93-8
n3:category
n3:containedIn
n7:271B4701-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4719-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B471B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B471C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B471E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4718-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4717-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B471A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4708-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4715-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4716-363D-11E5-9242-09173F13E4C5